Massive Bio, an industry leader in AI-powered clinical trial enrollment, has introduced Patient Connect, an innovative portal designed to enhance cancer patients’ access to clinical trials worldwide.
Patient Connect empowers patients by providing:
• Access to their medical records to enable in-depth AI analysis
• Identification of optimal clinical trial options based on their medical profile
• Personalized clinical trial matching reports for informed decision-making
Patients can access their matching results for over 16,000 cancer trials with a simple sign-up. To date, Massive Bio has connected patients to over 33,000 clinical trial sites, showcasing the efficiency of its AI platform.
Beyond technological solutions, Massive Bio offers personalized support through its concierge services. Patient relations coordinators, MDs, and oncology nurses provide guidance and assistance throughout the enrollment process, addressing any concerns or logistical challenges.
For healthcare providers, Massive Bio’s Clinical Network empowers them to:
• Review patients’ pre-screening results
• Monitor the enrollment process
This comprehensive patient-provider engagement model increases clinical trial enrollment globally, offering hope for better cancer outcomes.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
